Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JTT-861 Capsules
JTT-861 · 1 trial · 1 indication
General Scoring Guideline: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
| Arm | Type | Description |
|---|---|---|
| JTT-861 Dose 1 | EXPERIMENTAL | JTT-861 Capsules Dose 1 orally once daily for 12 weeks |
| JTT-861 Dose 2 | EXPERIMENTAL | JTT-861 Capsules Dose 2 orally once daily for 12 weeks |
| Placebo | EXPERIMENTAL | Placebo Capsules orally once daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| JTT-861 Capsules | DRUG | Active drug capsules containing JTT-861 |
| Placebo Capsules | DRUG | Placebo capsules matching in appearance to the active drug capsules |
Inclusion Criteria: * Has a clinical diagnosis of symptomatic heart failure (HF) ≥90 days prior to the Screening Visit; * Is in New York Heart Association (NYHA) functional class II or III at the Screening Visit; * Is on stable, guideline-directed therapy for HF, consistent with American Heart Asso...
JTT-861 is an investigational small molecule being developed for chronic heart failure, specifically heart failure with reduced ejection fraction. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
JTT-861 targets PDHK, which stands for pyruvate dehydrogenase kinase. By inhibiting PDHK, the drug aims to modulate cardiac energy metabolism, which is relevant to its potential therapeutic effect in chronic heart failure.
JTT-861 is being developed by Icon Plc, a company publicly traded under the ticker symbol ICLR. The drug is currently in Phase 2 clinical trials for chronic heart failure.
JTT-861 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies and is still undergoing clinical trials to evaluate its efficacy and safety.
JTT-861 is being studied in a Phase 2 clinical trial with the identifier NCT06017609. This trial is evaluating the efficacy, safety, and tolerability of JTT-861 in subjects with heart failure with reduced ejection fraction. The trial is active but not recruiting participants.
Yes, JTT-861 is also known as JTT-861 Capsules. The drug is administered in capsule form, and both names refer to the same investigational medication being developed for chronic heart failure.